Biotech Values

[DewDiligence]

BMY CHECKMATE-026 post-mortem:

Today’s PR is the first time BMY disclosed the PD-L1-expresssion threshold (≥5%) in CHECKMATE-026.

In retrospect, we can surmise that Opdivo would’ve had a better chance in first-line NSCLC if they had chosen a higher PD-L1-expression threshold than 5%; however, this was an instance where the science and the business exigencies were pulling in opposite directions.